Akawi N, McRae J, Ansari M, Balasubramanian M, Blyth M, Brady AF, et al. Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4,125 families. Nat Genet. 2015;47:1363–9.
Kernohan KD, McBride A, Xi Y, Martin N, Schwartzentruber J, Dyment DA, et al. Loss of arginine methyltranserase PRMT7 results in syndromic intellectual disability with microcephaly and brachydactyly. Clin Genet. 2017;91:708–16.
Agolini E, Dentici ML, Bellacchio E, Alesi V, Radio FC, Torella A, et al. Expanding the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review. Clin Genet. 2018;93:675–81.
Valenzuela I, Segura-Puimedon M, Rodríguez-Santiago B, Fernández-Alvarez P, Vendrell T, Armengol L, et al. Further delineation of the phenotype caused by the loss of functional mutations in PRMT7. Eur J Med Genet. 2019;62:182–5.
Birnbaum R, Yosha-Orpaz N, Yanoov-Sharav M, Kidron D, Gur H, Yosovich K, et al. Prenatal and postnatal presentation of PRMT7-related syndrome: Expanding phenotypic manifestations. Am J Med Genet A 2019;179:78–84.
Poquérusse J, Whitford W, Taylor J, Alburaiky S, Snell RG, Lehnert K, et al. New PRMT7 mutation in a rare case of dysmorphism and intellectual disability. J Hum Genet. 2022;67:19–26.
Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, et al. Neonatal Anthropometric Charts: The Italian Neonatal Study Compared to Other European Studies. J Pediatr Gastroenterol Nutr. 2010;51:353–61.
Growth calculator 4. [Online] http://www.weboriented.it/gh4/.
Tanner JM. Assessment of skeletal maturity and prediction of adult height (TW2 method). 2. Academic press; 1983.
Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47:865–88.
Mantovani G, de Sanctis L, Barbieri AM, Elli FM, Bollati V, Vaira V, et al. Pseudohypoparathyroidism and epigenetic anomalies of the GNAS: clinical evaluation of Albright’s hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab. 2010;95:651–8.
Linglart A, Maupetit-Méhouas S, Silve C. GNAS – Loss of function disorders and the role of imprinting. Horm Res Paediatr. 2013;79:119–29.
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Care of the child born small for gestational age through adulthood: a consensus statement from the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804–10.
De Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in children treated with growth hormone and with growth hormone deficiency. J Clin Endocrinol Metab. 2007;92:925–31.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after continuous long-term growth hormone (GH) treatment in short children born small for birth Gestational Age: Results of a Double Randomized Trial – Blinded Dose-Response GH Trial. J Clin Endocrinol Metab. 2003;88:3584–90.
Ranke MB, Lindberg A. KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disturbances: orientation of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95:1229–37.
Bang P, Ahmed SF, Argente J, Backeljauw P, Bettendorf M, Bona G, et al. Identification and management of poor response to growth-promoting therapy in children of short stature. Clin Endocrinol (Oxf). 2012;77:169–81.
Kelnar CJ. Growth hormone therapy in Noonan syndrome. Hor Res. 2000;53:77–81.
Muthuvel G, Dauber A, Alexandrou E, Tyzinski L, Andrew M, Hwa V, et al. Treatment of short stature in aggrecan-deficient patients with recombinant human growth hormone: response at one year. J Clin Endocrinol Metab. 2022;107:e2103–9.
Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf). 2010;72:721–8.
Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K. Efficacy and safety of two doses of Norditropin((R)) (somatropin) in people with short stature due to Noonan syndrome: a randomized study over 2 years, double blind multicentre trial in Japanese patients. Endocr J. 2018;65:159–74.
Dahlgren J, Albertsson-Wikland K. GH reactivity in children with Noonan syndrome versus Turner syndrome. Before Endocrinol (Lausanne). 2021;12:737893.
Chatelain P, Colle M, Nako JP, Le Luyer B, Wagner K, Berlier P, et al. Optimization of growth hormone dosing in children born small for gestational age: an open-label, randomized study of children in the fourth year of treatment. Horm Res Paediatr. 2012;77:156–63.
Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height in children with idiopathic short stature: a systematic review. BMJ 2011;342:c7157.
Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. Diagnosis, genetics and therapy of short stature in children: an international perspective from a growth hormone research society. Horm Res Paediatr. 2019; 92: 1–14.